Pfizer Inc. ($PFE) has sold its stake worth $3.26 billion in UK-based consumer healthcare company Haleon PLC ($GB:HLN). With ...

The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10 ...

Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- , Inc., “The ...

The immune checkpoint inhibitors market is primarily driven by the increasing prevalence of cancer, rising investment in ...

Pfizer is following the example of GlaxoSmithKline and Novartis, two big pharmas that have already appointed chief digital officers to transform R&D and relationships with customers. Last year ...

diff vaccine candidate in clinical development is GlaxoSmithKline, whose GSK2904545A is in phase 1. PF-06425090 has been held up as one of the top prospects in Pfizer's pipeline, with blockbuster ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...